Adjuvant Treatment: Old and New Immunotherapy in Non-Muscle-Invasive Bladder Cancer

2018 ◽  
pp. 43-47
Author(s):  
J. Palou ◽  
F. Pisano
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Treatment ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

1100 Adjuvant treatment of G2/high grade non-muscle invasive bladder cancer: Mytomicin or Bacillus Calmette-Guèrin?

2014 ◽  
Vol 13 (1) ◽  
pp. e1100-e1100a
Author(s):  
J. Palou ◽  
O. Rodríguez Faba ◽  
S. Skrobot ◽  
J.A. Peña ◽  
J.M. Gaya ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Treatment ◽  
Invasive Bladder Cancer ◽  
High Grade ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

EGFR cell expression during adjuvant treatment after transurethral resection for non-muscle invasive bladder cancer

2019 ◽  
Vol 18 (1) ◽  
pp. e1463-e1464
Author(s):  
F. Di Maida ◽  
A. Mari ◽  
C. Scalici Gesolfo ◽  
A. Cangemi ◽  
R. Allegro ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Treatment ◽  
Transurethral Resection ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Cell Expression

Place of adjuvant treatment in nonurothelial muscle invasive bladder cancer patients after radical cystectomy

2015 ◽  
Vol 14 (6) ◽  
pp. e1332-e1332a
Author(s):  
G. Glück ◽  
D. Stanculeanu ◽  
M. Hortopan ◽  
M. Chirita ◽  
R. Stoica ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Radical Cystectomy ◽  
Adjuvant Treatment ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer

2021 ◽  
pp. 1-8
Author(s):  
Michele Zazzara ◽  
Arjan Nazaraj ◽  
Marcello Scarcia ◽  
Giuseppe Cardo ◽  
Roberto Carando ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Adjuvant Treatment ◽  
Invasive Bladder Cancer ◽  
Intravesical Therapy ◽  
Progression Rate ◽  
Muscle Invasive Bladder Cancer ◽  
Free Survival ◽  
Muscle Invasive

<b><i>Background:</i></b> Although TURB of tumor (TURBT) by itself can eradicate a non-muscle-invasive bladder cancer (NMIBC) completely, these tumors commonly recur and can progress to MIBC. It is, therefore, necessary to consider adjuvant therapy in most patients. The primary objective of the present study was to report our experience with EMDA/MMC and BCG, considering efficacy, progression, and recurrence, as adjuvant therapy in NMIBC patients; the secondary objective was to assess the efficacy of EMDA/MMC versus BCG as a comparative treatment. <b><i>Methods:</i></b> Between April 2016 and February 2020, a series of 216 patients, with a diagnosis of intermediate- and high-risk NMIBC after TURBT, underwent adjuvant intravesical therapy. In 26 cases with a failure of the treatment, in patients unfit and unwilling for radical cystectomy, a repeated intravesical therapy was performed (2 had a twice repetition). Out of 244 adjuvant therapies, 140 EMDA/MMC and 104 BCG treatments were done. The following data were collected for each patient: baseline demographics and clinical data and perioperative and postoperative data. Overall patients’ adjuvant intravesical therapies were included in a prospectively maintained institutional database, and a retrospective chart review was performed. We collected data on 2 main outcomes, recurrence-free survival (defined as a negative cystoscopy, cytology, and/or histology at the evaluation time point) and progression-free survival (defined as a negative cystoscopy or a nonprogressive tumor recurrence). <b><i>Results:</i></b> The NMIBC progression rate was higher in BCG than EMDA/MMC but not statistically significant (respectively, 4.2% vs. 2.5%; <i>p</i> = 0.703). In the overall population, the risk of NMIBC recurrence was higher after BCG than EMDA/MMC (<i>p</i> = 0.025). In the subgroups of 59 paired patients with similar characteristics, no difference was observed between groups in NMIBC progression and recurrence. <b><i>Conclusions:</i></b> Our findings suggest that EMDA/MMC and BCG are safe and reproducible approaches as adjuvant treatment in NMIBC. EMDA/MMC permits to achieve a fine oncological management as adjuvant treatment in NMIBC, which is not less than that obtained with BCG.

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer

Urology ◽  
2020 ◽  
Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Racial Disparities ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document